Clive Page – författare

The consequences for diseases involving the immune system such as AIDS, and chronic inflammatory diseases such as bronchial asthma, rheumatoid athritis, and atherosclerosis, now account for a considerable economic burden to governments worldwide. In response there has been an enormous research effort investigating the basic mechanisms underlying such diseases, and a tremendous drive to identify novel therapeutic applications for their preventions and treatment. Though a plethora of immunological studies have been published in recent years, little has been written about the implications of such research for drug development. As a consequence, this area has not gained the prominence of other new fields such as molecular pharmacology or neuropharmacology, and a focal information source for many pharmacologists interested in diseases of the immune system remains unpublished. The Handbook of Immunopharmacology series provides such a source through the commissioning of a comprehensive collection of volumes on all aspects immunopharmacology. Editors have been sought after for each volume who are not only active in their respective areas of expertise, but who also have distinctly pharmacological bias to their research. The series follows three main themes, each represented by volumes on individual component topics. The first covers each of the major cell types and classes of inflammatory responses that can affect them ("Systems"). The third covers different classes of diseases as well as those under development ("Drugs").

Non-selective inhibitors of cyclic nucleotide phosphodiesterase (PDE), such as theophylline, have been used extensively since 1958. In the decade of the '70s, various PDE isoenzymes were defined which led to the development of the second generation of PDE inhibitors. Currently a variety of these new inhibitors are under test as potential anti-inflammatory drugs. During the past five years, molecular biology has revealed a superfamily of these phosphodiesterase isoenzymes. This book summarizes the present state of knowledge, as well as giving a comprehensive description of the compounds available. It will be invaluable for everyone who wants to choose the most suitable PDE inhibitor for their research or who is dealing with such drugs in a clinical setting. Utilizes actual testing and research of new PDE inhibitors Valuable for researchers and students alike

The realisation that epithelial tissues are not simply passive barriers to the adsorption of materials into internal environments has brought about an enormous growth of investigation of mucosal functions and their active and passive protective roles. Epithelia are highly organized but complex structures, subserving numerous functions, including immunological defence. The use of pharmacological tools in these systems is increasing, which is improving our understanding of epithelial immunobiology. This volume adopts a step-by-step approach, whereby each chapter builds upon the previous one, progressively adding important foundation information, culminating in a series of chapters concerning particular epithelia, including respiratory, gastrointestinal, renal and ocular. The result is a comprehensive but integrated treatise of epithelial function and its immunopharmacology, which aims to serve as an appropriate starting point at which the clinical pulmonologist and the research scientist can obtain an appreciation of some aspects of epithelial immunopharmacology as they are currently understood.

The consequences of diseases involving the immune system such as AIDS, and chronic inflammatory diseases such as bronchial-asthma, rheumatoid arthritis and atherosclerosis, now account for a considerable economic burden to governments worldwide. In response there has been an enormous research effort investigating the basic mechanisms underlying such diseases, and a tremendous drive to identify novel therapeutic applications for their prevention and treatment. Though a plethora of immunological studies have been published in recent years, little has been written about the implications of such research for drugs development. As a consequence, this area has not gained the prominence of other fields such as molecular pharmacology or neuropharmacology, and a focul information source for the many pharmacologists interested in diseases of the immune system remains unpublished.The Handbook of Immunopharmacology series provides such a source through the commissioning of a comprehensive collection of volumes on all aspects of immunopharmacology. Editors have been sought after for each volume who are not only active in their respective areas of expertise, but who also have a distinctly pharmacological bias to their research.The series follows three main themes, each represented by volumes on individual component topics. The first covers each of the major cell types and classes of inflammatory mediators ("cells and mediators"). The second covers each of the major organ systems and the diseases involving the immune and inflammatory responses that can effect them ("systems"). The third covers different classes of drugs currently used to treat these diseases as well as those under development ("drugs").This volume provides a comprehensive overview of the adhsion molecules, processes and concepts that govern both inflammatory and infectious diseases, and also deals in detail with the specific in vivo pathways involved.The first chapter introduces some of the molecules that mediate leukocyte adhesion and ranges from their discovery using monoclonal antibodies and a congenital adhesion deficiency, to their antagonism in preliminary clinical trials as novel therapeutics. An in-depth analysis of the structure, distribution and function of the cell surface glycoproteins that regulates lymphocyte (specific immune response), granulocyte (acute inflammatory response) and metastatic cell (malignant processes) adhesions respectively is provided by the next three chapters. Chapters 5 and 7 detail the molecular structure, intracellular pathways, specificty of carbohydrate interactions, and signalling of the molecules that regulate leukocyte-leukocyte and leukocyte-mesenchymal cell interactions.There follows an exploration into the contributions of specific molecules in inflammatory diseases in various organs from chapters 8-11. The concluding part is unique to this volume by reviewing the comparable, and in some cases same, cell surface molecules that mediate virus, bacteria and parasite interactions with host cells.The research is far from complete, but Adhesion Molecules is extremely comprehensive and will be a valuable resource for many a year to come.

Standardizing Pharmacology: Assays and Hormones, Volume Two in the Discoveries in Pharmacology series, presents selected articles from historic discoveries that are enhanced with commentary from contemporary scholars who present discussions on the importance of each chapter, along with an updated bibliography on the subject and contributions from a Nobel Prize winner and other pioneers in pharmacology. Academic and industry researchers in pharmacology and medicine, as well as advanced students will find this series a useful teaching tool and launch to new discoveries.

Sections cover key discoveries in receptor theory, pharmacological methods and the development of hormone therapy, including J. Parascandola on the development of receptor theory, R.S. Yalow on radioimmunoassay, M. van Rossum and J.T L.A. Hurkmans on bioassays, M. Tausk on androgen therapy and C. Djerassi on oral contraceptives, with commentaries from experts such as T. H�kfelt and V.C. Jordan.

Contains primary-source documents currently unavailable elsewhere Presents the science behind major pharmacological breakthroughs by those who discovered them Includes commentary contextualizing the importance of discoveries and related readings

Discoveries in Pharmacology: Volume 1: Nervous system and hormones (2nd Ed.) presents selected articles from the historic Discoveries in Pharmacology series enhanced with commentary from contemporary scholars about the reception and importance of the chapter along with an updated bibliography on the subject with contributions from a Nobel Prize winner and other pioneers in Pharmacology. The Discoveries in Pharmacology series brought acknowledged experts in their fields together to provide first-hand accounts of important pharmacological discoveries discussing the scientific background and stories behind these pivotal moments. They allow a true understanding of the means by which pharmacological discoveries are made. This volume brings forth discussions on key discoveries in psycho- and neuro-pharmacology, haemodynamics, and hormones including chapters on antipsychotic agents by Nobel winner Anders Carlsson, Willy Haefely on benzodiazepine, and butyrophenone-type neuroleptics by P. A. J. Janssen and J. P. Tollenaere. Academic and industry researchers in pharmacology and medicine, as well as advanced students in the area will find this series a useful teaching tool and launch to new discoveries. Chapters can also be used to supplement course material in pharmacology and medical courses. It will also be of interest to those who are interested in the history of medicine.

Contains primary-source documents currently unavailable Presents the science behind major pharmacological breakthroughs by those who discovered them Includes commentary that contextualizes the importance of discoveries and related readings